The latest sales price reference information of capmatinib in China

Capmatinib (Capmatinib) is a targeted drug targeting MET exon 14 skipping mutation (METex14). It has been successfully launched in China and has been included in the national medical insurance system. With the coverage of medical insurance, the financial burden of patients using capmatinib has been significantly reduced. However, because the drug has not been on the market for a long time, the current supply in some urban hospital pharmacies is not sufficient. When purchasing directly in China, patients may need to make an appointment in advance or obtain it through designated hospital channels. Overall, the actual payment amount after medical insurance has dropped significantly, making it more accessible than the high cost before reimbursement.

In the domestic market, the price of capmatinib is regulated by medical insurance policies, and patients’ out-of-pocket costs vary according to regions and medical insurance reimbursement ratios. Generally speaking, after being included in medical insurance reimbursement, the patient's personal expenditure is much lower than the original price, allowing more patients to insist on using the drug for a long time. For eligible patients, medical assistance or charitable assistance programs can also be applied to further alleviate financial stress. Therefore, the domestic version of capmatinib is relatively patient-friendly in terms of price.

For patients who cannot obtain the drug in time at home, some people will also choose to purchase capmatinib through overseas channels. In the international market, the price of capmatinib’s original drug is generally high, with most costing tens of thousands of yuan per box, posing a heavy financial burden. Such prices are often unaffordable for the average patient in the long term, so some patients will consider other channels for alternative options.

Compared with the expensive original drug, generic versions of capmatinib have appeared in overseas markets, especially the Lao version. Its price is obviously more affordable, with a box costing about more than 2,000 yuan, which saves several times the cost compared to the original drug. Although they are generic drugs, their active ingredients and efficacy are basically the same as those of the original drugs, making them the main choice for some patients under financial pressure. Taken together, patients can make a balance between domestic medically insured drugs or overseas generic drugs based on their own financial situation and medication needs.

Reference link:https://www.drugs.com